RZLT Rezolute, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1509261 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.9%
ROA-61.2%
ROIC (approx.)-60.4%
Asset turnover—
Leverage & solvency
Liabilities / assets10.5%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $12.81M | $14.89M | $11.41M | $14.35M | $13.15M | $20.86M | $15.28M | $12.63M |
| SG&A expense | $6.58M | $6.67M | $5.95M | $9.87M | $6.67M | $4.99M | $4.74M | $4.45M |
| Operating income | -$19.39M | -$21.56M | -$17.37M | -$24.22M | -$19.82M | -$25.85M | -$20.02M | -$17.08M |
| Net income | -$18.49M | -$20.49M | -$16.17M | -$22.77M | -$18.15M | -$24.39M | -$18.91M | -$15.73M |
| EBITDA | -$19.38M | -$21.55M | -$17.36M | -$24.21M | -$19.81M | -$25.84M | -$20.02M | -$17.07M |
| EPS (basic) | -0.18 | — | -0.16 | -0.22 | -0.18 | — | -0.27 | -0.22 |
| EPS (diluted) | -0.18 | — | -0.16 | -0.22 | -0.18 | — | -0.27 | -0.22 |
| Weighted avg. shares (diluted) | 104.78M | — | 104.04M | 103.69M | 103.42M | — | 70.03M | 69.94M |
| Balance sheet | ||||||||
| Cash & equivalents | $8.15M | $10.62M | $11.24M | $11.94M | $9.10M | $94.11M | $14.60M | $8.93M |
| Short-term investments | $81.85M | $97.19M | $109.03M | $120.99M | $143.10M | $73.75M | $72.30M | $87.61M |
| Current assets | $93.83M | $110.51M | $122.05M | $135.11M | $154.71M | $171.15M | $88.73M | $98.69M |
| PP&E, net | $33,000 | $41,000 | $49,000 | $57,000 | $64,000 | $72,000 | $80,000 | $87,000 |
| Total assets | $96.01M | $112.85M | $125.46M | $138.63M | $158.66M | $175.49M | $94.74M | $112.01M |
| Current liabilities | $9.46M | $11.42M | $7.70M | $9.53M | $10.21M | $11.91M | $10.53M | $10.61M |
| Total liabilities | $10.06M | $12.16M | $8.62M | $10.63M | $11.50M | $13.36M | $12.17M | $12.42M |
| Shareholders' equity | $85.95M | $100.69M | $116.83M | $128.00M | $147.17M | $162.13M | $82.57M | $99.59M |
| Shares outstanding | 96.72M | 96.41M | 96.29M | 95.55M | 91.04M | 87.00M | 60.54M | 60.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.78M | -$13.15M | -$13.73M | -$20.32M | -$17.43M | -$22.00M | -$17.40M | -$13.67M |
| Investing cash flow | $15.77M | $12.30M | $12.28M | $22.81M | -$68.49M | $346,000 | $23.05M | $11.47M |
| Financing cash flow | $552,000 | $227,000 | $747,000 | $356,000 | $911,000 | $101.16M | $10,000 | $657,000 |
| Depreciation & amortization | $8,000 | $8,000 | $8,000 | $7,000 | $8,000 | $8,000 | $7,000 | $8,000 |
| Stock-based compensation | $3.27M | $4.10M | $4.42M | $3.41M | $2.53M | $2.37M | $1.91M | $1.45M |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.